Lipid profiles in patients with juvenile idiopathic arthritis: a systematic literature review and meta-analysis

Zhao, Wen-Jia; Deng, Jiang-Hong; Li, Cai-Feng

doi:10.1186/s12944-023-01885-1

Lipids in Health and Disease

Table 2 Characteristics and design of the included studies

From: Lipid profiles in patients with juvenile idiopathic arthritis: a systematic literature review and meta-analysis

Study	Design	Country/ Region	Sample size		Age (mean ± SD)		Sex (female, %)		Disease duration (years)	Classification criteria	Diagnosis	Active disease (%)	Treatment at enrollment	Measurement
Study	Design	Country/ Region	Case	Control	Case	Control	Case	Control	Disease duration (years)	Classification criteria	Diagnosis	Active disease (%)	Treatment at enrollment	Measurement
Hussain, 2020 [17]	CS	India	81	78	12.5(8–16)^a	13(9–17)^a	38.2	42	3 (2–6)^a	ILAR criteria	JIA	42	Steroids, NSAIDs, and MTX	BMI VLDL LDL HDL
Jednacz, 2015 [18]	CS	Poland	30	20	14.0 ± 1.8	14.4 ± 1.8	76.7	75		ILAR criteria	JIA	67	Steroids, DMARDs, and TNF inhibitors	BMI TG TC HDL-C LDL-C
Breda, 2013 [19]	CC	Italy	38	40	7.05 ± 2.39	6.34 ± 2.25	68.4	55		ILAR criteria	JIA		NSAIDs and MTX	BMI TC TG HDL-C LDL-C
Pugliese, 2015 [20]	CS	Brazil	35	35	11.90 ± 2.0	12.50 ± 3.0			6.0 (0.25–13)^a	ILAR criteria	JIA		Steroids, DMARDs, and TNF inhibitors	TC HDL LDL VLDL TG
Gonçalves, 2007 [21]	CS	Brazil	51	52	11.3 ± 4.2	12.5 ± 3.5	72.6	80.1		ILAR criteria	JIA		Steroids, NSAIDs, and DMARDs	HDL LDL VLDL TG
Tselepis, 1999 [22]	CO	France	26	22	11 ± 3	11 ± 4	53.9	63.6	4.5 (0.5–10)^a	ACR criteria	JRA	53.9	Steroids, NSAIDs, and MTX	BMI HDL-C LDL-C TG TC Apo-A1 Apo-B
Bos, 2016 [23]	CC	Netherlands	76	131	10.4 ± 1.2	10.0 ± 1.4	66	63	3.6 ± 2.7	ILAR criteria	JIA		NSAIDs, and DMARDs	BMI
Więch, 2018 [24]	CS	Poland	46	46	12.74 ± 3.85	12.70 ± 3.80				ILAR criteria	JIA			BMI
Risum, 2019 [25]	CO	Norway	59	59	13.6 ± 2.2	13.5 ± 2.6	85	85	7.9 ± 3.8	ILAR criteria	JIA	33.9		BMI
Turoňová, 2018 [26]	CO	Slovakia	25	25	13.91 ± 2.98	14.01 ± 3.0	56	56	5.48 ± 3.91	ILAR criteria	JPSA		Steroids, NSAIDs, and DMARDs	HDL LDL TG TC
Studart, 2015 [27]	CO	Brazil	50	20	13.4 ± 4.4	11 ± 4	62	55	5.5 ± 4.3	ILAR criteria	JIA			BMI
Bakkaloglu, 1996 [28]	CS	Turkey	19	18						ACR criteria	JCA			BMI HDL LDL VLDL TG TC Apo-A1 Apo-B
Mani,2016 [29]	CO	USA	29	15	17.3 ± 6.7	21.7 ± 6.8	62.1	53.3		ILAR criteria	JIA		NSAIDs, and DMARDs	BMI HDL TG HDL-C LDL-C Apo-A1
Aranda-Valera,2020 [30]	CS	Spain	25	25	25.11 ± 7.21	27.21 ± 2.54	56	52	13.47 ± 5.47	ILAR criteria	JIA		Steroids, NSAIDs, DMARDs, and TNF inhibitors	BMI TG TC HDL-C LDL-C Apo-B
Sun,2019 [31]	CO	Mainland, China	22	45						ILAR criteria	sJIA	68.2		TG TC HDL-C LDL-C
Shen,2012 [32]	CO	Taiwan, China	27	232	14.58 ± 4.12	14.15 ± 3.76	40.7	37.5		ILAR criteria	JIA	46.6		BMI TG TC HDL-C LDL-C

ACR American College of Rheumatology, Apo Apolipoprotein, BMI Body mass index, CC a case‒control study, CO Cohort study, CS a cross-sectional study, DMARDs Disease-modifying anti-rheumatic drugs, HDL High-density lipoprotein, HDL-C High-density lipoprotein cholesterol, ILAR International League of Associations for Rheumatology, JCA Juvenile chronic arthritis, JIA Juvenile idiopathic arthritis, JPSA Juvenile psoriatic arthritis, JRA Juvenile rheumatoid arthritis, LDL Low-density lipoprotein, LDL-C Low-density lipoprotein cholesterol, MTX Methotrexate, NSAIDs Nonsteroidal anti-inflammatory drugs, sJIA Systemic juvenile idiopathic arthritis, TC Total cholesterol, TNF: tumor necrosis factor, TG Triglyceride, VLDL Very low-density lipoprotein
Note: ^aAverage age (upper quartile, lower quartile).

Back to article page

ISSN: 1476-511X

Contact us

General enquiries: journalsubmissions@springernature.com